Hepatoma Derived Growth Factor Is the Target of Metformin

Presentation Number: SAT 580
Date of Presentation: April 1st, 2017

Xin Wang*1, Min Zha2 and Ting Tian3
1Jiangsu Province Hospital of TCM/Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China, 2Nanjing Medical University, 3Jiangsu Province Hospital of TCM


Background: Hepatoma derived growth factor (HDGF) is a key growth factor in development and progression of tumors [1]. Recent research disclosed metformin has the anti-tumor potential[2]. However, it is not clear whether the anti-tumor effect of metformin depends on HDGF.

Aim of the study: To investigate impact of metformin on serum HDGF concentration in diabetic patients.

Patients and Methods: 142 diabetic patients and 15 healthy individuals were recruited in the study. Diabetic patients were grouped based on whether metformin was included in their medications. Sera HDGF concentration was measured by ELISA. HDGF concentrations between each two groups were compared by t test.

Results: Sera HDGF concentration elevated in diabetic patients (137.30±10.38 ng/ml in diabetic patients vs 81.38±22.84 ng/ml in healthy individual, p=0.029). Patients treated with metformin, either as monotherapy or combined with other hypoglycemic agents, exhibited lower sera HDGF concentration than treated without metformin (81.69±10.06 ng/ml in metformin treated group, n=40 vs 159.20±13.31 ng/ml in metformin-free group, n=102, p<0.001). Insulin treated patients had higher sera HDGF concentration than oral hypoglycemic agents treated patients (213.96±20.14 in insulin treated group, n=29 vs 157.26±18.46 ng/ml in oral hypoglycemic agents treated group n=103, p<0.0001, patients treated by insulin combined with metformin were excluded from either group).

Conclusion: Our findings suggested HDGF was the target of metformin. Inhibiting the secretion of HDGF may be part of the mechanism of anti-tumor effect of metformin.


Nothing to Disclose: XW, MZ, TT